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Background: Epstein-Barr Virus (EBV) is one of the most prevalent causes of viral infec-
tion in humans. EBV infection stage (acute, past, or absent infection) is typically determined 
using a combination of assays that detect EBV-specific markers, such as IgG and IgM an-
tibodies against the EBV viral capsid antigen (VCA) and IgG antibodies against the EBV 
nuclear antigen (EBNA). We compared the diagnostic performance and agreement of re-
sults between three commercial EBV antibody assays using an EBV performance panel 
(SeraCare Life Science, Milford, MA, USA) as a reference.
Methods: EBV antibody tests of EBV VCA IgM, VCA IgG, and EBNA IgG antibodies were 
performed by the Architect (Abbott Diagnostics, Wiesbaden, Germany), Liaison (DiaSorin, 
Saluggia, Italy), and Platelia (Bio-Rad, Marnes-la-Coquette, France) assays. Agreement 
between the three assays was evaluated using 279 clinical samples, and EBV DNA and 
antibody test results were compared. 
Results: The three EBV antibody assays showed good diagnostic performance with good 
and excellent agreement with the performance panel (kappa coefficient, >0.6). The over-
all VCA IgM positivity rate was higher in EBV DNA-positive samples than in EBV DNA-neg-
ative samples for all three EBV antibody assays (P =0.02). The three EBV antibody assays 
exhibited good agreement in results for the clinical samples.
Conclusions: The diagnostic performance of the three EBV antibody assays was accept-
able, and they showed comparable agreement in results for the clinical samples. 
Key Words: Epstein-Barr virus, Assay, Diagnostic performance, DNA, Antibody, Immuno-
globulin
Received: August 17, 2017
Revision received: November 28, 2017
Accepted: May 3, 2018
Corresponding author: Hyon-Suk Kim
 https://orcid.org/0000-0001-5662-7740
Department of Laboratory Medicine, Yonsei 
University College of Medicine, 50-1 
Yonsei-ro, Seodaemun-gu, Seoul 03722, 
Korea
Tel: +82-2-2228-2443
Fax: +82-2-364-1583
E-mail: kimhs54@yuhs.ac
© Korean Society for Laboratory Medicine
This is an Open Access article distributed under 
the terms of the Creative Commons Attribution 
Non-Commercial License (http://creativecom-
mons.org/licenses/by-nc/4.0) which permits 
unrestricted non-commercial use, distribution, 
and reproduction in any medium, provided the 
original work is properly cited.
INTRODUCTION
The Epstein-Barr virus (EBV) is one of the most prevalent causes 
of viral infection in humans. EBV has been linked to infectious 
mononucleosis [1]. Humans are the only natural hosts of EBV. 
Oral transmission is the primary route of infection in adolescents 
and young adults [2]; however, EBV can also be acquired via 
blood transfusions, hematopoietic stem cell transplantation, or 
solid organ transplants, and these infections can be life-threat-
ening [3-6].
In immunocompromised patients (particularly in solid organ 
transplant recipients), EBV DNA detection tests are performed 
within three months of transplantation and at least once per 
year in stable transplanted patients [4, 7]. However, these tests 
do not reflect EBV infection status in all patients, as the virus 
can exist in B lymphocytes and possess Herpesviridae latency 
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[8]. Antibody tests for EBV, such as those involving IgM and IgG 
antibodies against the EBV viral capsid antigen (VCA) and an 
IgG antibody against the EBV nuclear antigen (EBNA), are also 
frequently used to determine EBV infection status. EBV infection 
stage is typically assessed using a combination of antibody as-
says. An ideal EBV testing panel, including a combination of an-
tibody assays for detecting EBV-specific antigens, should be 
able to detect all serologic infection statuses (acute, past, and 
absent infections). 
Although the immunofluorescence assay (IFA) is considered 
the gold standard for the detection of VCA and EBNA IgG [9], 
chemiluminescence immunoassays (CLIA) using automated 
analyzers are also widely used because of their objective inter-
pretation of results, high throughput, and low labor intensive-
ness [9-15]. Different commercial EBV antibody assays often 
show varying test results, thus hindering the interpretation of 
patient EBV infection status [9, 10, 16]. Reliable test results are 
needed for an exact diagnosis of EBV infection; therefore, EBV 
assays used in diagnostic laboratories must be evaluated for 
their accuracy, performance, and reliability. 
Although many studies have compared commercial EBV as-
says [9-14], the diagnostic performance of the assays has not 
been evaluated using a standard EBV performance panel (Sera-
Care Life Science, Milford, MA, USA) covering various EBV in-
fection status. To fill this gap, we evaluated the diagnostic per-
formances of three commercial EBV antibody assays, Architect 
(Abbott Diagnostics, Wiesbaden, Germany), Liaison (DiaSorin, 
Saluggia, Italy), and Platelia (Bio-Rad, Marnes-la-Coquette, 
France) assays, using an EBV performance panel and com-
pared the results of these three commercial assays in clinical 
samples of patients with suspected EBV infection.
METHODS
1. Study samples
A total of 279 samples (from 123 males and 156 females with a 
median age of 25 years, range 11 months–96 years) for which 
an EBV PCR test and antibody assays (VCA IgM, VCA IgG, and 
EBNA IgG) were concurrently ordered, were collected from 
March 2015 to March 2016. All samples were derived from im-
munocompetent patients for the diagnosis of EBV infection. We 
excluded samples from immunocompromised patients (e.g., 
those with cancer, organ transplant recipients, or those with 
other infectious diseases). The Liaison assay was performed on 
the requested date for EBV antibody tests, and the residual 
samples were stored at –20°C, following separation for the Ar-
chitect assay and Platelia assay and between assay testing. This 
study was approved by the Institutional Review Board (IRB) of 
Severance Hospital, Seoul, Korea. The IRB approved exemption 
for written informed consent, because this study was performed 
using stored residual samples after testing and based on a ret-
rospective chart review.
2. EBV antibody assays
The Liaison assay was performed before the Architect and Plate-
lia assays. The Liaison test is based on CLIA and samples were 
analyzed using the Liaison analyzer (DiaSorin); the Architect as-
say is a chemiluminescent microparticle immunoassay (CMIA) 
and was performed using the Architect i2000 analyzer (Abbott 
Diagnostics); and the Platelia test is an ELISA that was performed 
manually. Optical densities of the Platelia test were quantified 
using the BEP III System (Siemens, Marburg, Germany). For 
the Platelia assay, serum samples were diluted 1:21 (10 μL+ 
200 μL) with the sample diluent provided with the assay kit. The 
instructions of the other tests did not recommend the use of se-
rum dilution. All assay procedures followed the manufacturers’ 
instructions (Table 1). 
3. EBV performance panel
The Anti-Epstein-Barr Virus Mixed Titer Performance Panel (Se-
raCare Life Science) includes 21 samples covering different 
EBV infection status (one seronegative, 13 past infections [VCA 
IgM-, VCA IgG+, EBNA IgG+], three acute primary infections 
[VCA IgM+, VCA IgG+, EBNA IgG-], three early phase acute pri-
mary infections [VCA IgM+, VCA IgG-, EBNA IgG-], and one 
transient infection or re-infection [VCA IgM+, VCA IgG+, EBNA 
IgG+]) and a data sheet for comparing the panel results with the 
test results of the commercial EBV assays.
Lyophilized aliquots of donor plasma were dissolved in dis-
tilled water prior to analysis. Tests were performed in duplicate 
using the three commercial EBV assays to reduce the likelihood 
of experimental or reagent errors. VCA IgM values >43.9 and 
>1.0 were considered positive according to the performance 
panel data sheet of the Liaison and Platelia assays, respectively; 
VCA IgG values >1.0 were considered positive for the Platelia 
EBV assay; and EBNA IgG values >21.9 and >1.0 in the Liai-
son and Platelia EBV assays, respectively, were considered posi-
tive. The positive and negative results of the panel samples, ob-
tained using the EBV antibody assays, were interpreted accord-
ing to the performance panel instructions, and EBV antibody 
assay results were determined following the instructions of each 
assay. 
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4. EBV DNA test
PCR for EBV DNA was performed using the artus EBV RG PCR 
Kit (Qiagen, Hilden, Germany) on Rotor-Gene Q Instrument (Qia-
gen) after extracting DNA from plasma with the QIAamp DNA 
Mini Kit (Qiagen, Dusseldorf, Germany) according to the manu-
facturer’s instruction. 
5. Statistical analysis
Kappa statistics, sensitivity, and specificity were calculated for 
VCA IgM, VCA IgG, and EBNA IgG based on the EBV performance 
panel results. We also calculated kappa statistics and the per-
centages of positive, negative, and total agreement between the 
Architect, Liaison, and Platelia EBV assays. Kappa values >0.75 
indicated excellent agreement, values between 0.40 and 0.75 
suggested fair to good agreement, and values <0.40 represented 
poor agreement. The percentage of total agreement between 
the assays represents the percentage of paired tests with identi-
cal results. Because “gray zone” or equivocal results cannot be 
interpreted as positive results and are mostly considered nega-
tive by clinicians, these results were grouped to evaluate kappa 
statistics and agreement percentages. The Student t-test was 
performed to determine the VCA IgM positive rate between the 
EBV DNA-positive and negative groups. P values<0.05 were 
considered statistically significant. To evaluate diagnostic perfor-
mance based on clinical diagnosis of EBV infection of clinical 
samples, Youden’s index and positive and negative Likelihood 
ratio were calculated. All statistical analyses were performed us-
ing Analyse-it, version 4.65 (Analyse-it Software, Ltd., Leeds, UK).
RESULTS
1. Diagnostic performance of the three EBV antibody assays
The duplicate EBV antibody results were the same in all three 
assays. The EBV performance panel exhibited good and excel-
lent agreement with the Architect, Liaison, and Platelia EBV an-
tibody assays, with Kappa coefficients>0.6 (Table 2). However, 
we observed poor agreement between the performance panel 
and the Liaison assay for VCA IgG (kappa coefficient, 0.35; Ta-
ble 2). One and two VCA IgM-positive EBV performance panel 
samples tested negative with the Architect and Platelia assays 
and Liaison assay, respectively; these changes affected the sen-
sitivity of the VCA IgM tests (sensitivity, 71.4–85.7%; Table 2). 
Two and three panel samples tested VCA IgG-positive with the 
Architect and Liaison assays, respectively, but were negative ac-
cording to the EBV performance panel (Table 2); this affected 
the specificity of the two assays. For EBNA IgG, three assays 
and EBV performance panel demonstrated similar results. 
2. Comparison of the EBV antibody and DNA assays
EBV DNA was detected in 74 of 279 (26.5%) patient samples 
(Table 3). Most EBV DNA-negative patients were also VCA IgM-
negative. The overall VCA IgM positivity rate was higher in EBV 
Table 1. Characteristics of the three Epstein-Barr virus antibody assays
Architect Liaison Platelia
VCA IgM VCA IgG EBNA IgG VCA IgM VCA IgG EBNA IgG VCA IgM VCA IgG EBNA IgG
Method CMIA CLIA ELISA
Sample Serum or plasma Serum or plasma Serum
Sample volume 25 μL (+150 μL dead volume) 20 μL (+150 μL dead volume) 10 μL
Assay duration ~30 min ~50 min ~150 min
Assay unit S/CO* U/mL ISR
Interpretation
   Nonreactive <0.50 <0.75 <0.50 <20 <20 <5 ≤0.90 ≤0.90 ≤0.90
   Gray zone/equivocal† 0.50 to  
<1.00
0.75 to  
<1.00
0.50 to  
<1.00
20 to  
<40
No equivocal 
zone
5 to  
<20
0.91 to  
<1.10
0.91 to  
<1.10
0.91 to  
<1.10
   Reactive ≥1.00 ≥1.00 ≥1.00 ≥40 ≥20 ≥20 ≥1.10 ≥1.10 ≥1.10
Antigen VCA p18 EBNA-1 p72 Synthetic peptide p18 EBNA-1 Affinity-purified VCA antigen Recombinant 
EBNA-1
EA IgG availability No Yes Yes
*Sample RLU/cut-off RLU; †Gray zone for Architect and Equivocal for Liaison and Platelia. 
Abbreviations: CLIA, chemiluminescence immunoassay; CMIA, Chemiluminescent microparticle immunoassay; EA, Epstein-Barr virus early antigen; EBNA, 
Epstein-Barr virus nuclear antigen; ELISA, enzyme-linked immunosorbent assay; ISR, immune status ratio; RLU, relative light unit; VCA, viral capsid antigen.
Park Y, et al.
Diagnostic performance of EBV antibody assays
https://doi.org/10.3343/alm.2018.38.5.458 www.annlabmed.org  461
Table 2. Diagnostic performance of the Architect, Liaison, and Platelia assays
Panel results (N) Kappa coefficient  
(95% CI)
Sensitivity, %  
(95% CI)
Specificity, %  
(95% CI)Positive Negative
VCA IgM
Architect Positive 6 0 0.89 (0.68–1.00) 85.7 (48.7–97.4) 100.0 (78.5–100.0)
Negative 1 14
Liaison Positive 5 0 0.77 (0.47–1.00) 71.4 (35.9–91.8) 100.0 (78.5–100.0)
Negative 2 14
Platelia Positive 6 0 0.89 (0.68–1.00) 85.7 (48.7–97.4) 100.0 (78.5–100.0)
Negative 1 14
VCA IgG
Architect Positive 17 2 0.62 (0.15–1.00) 100.0 (81.6–100.0) 50.0 (15.0–85.0)
Negative 0 2
Liaison Positive 17 3 0.35 (−0.17–0.87) 100.0 (81.6–100.0) 25.0 (4.6–69.9)
Negative 0 1
Platelia Positive 14 0 0.64 (0.29–0.99) 82.4 (59.0–93.8) 100.0 (51.0–100.0)
Negative 3 4
EBNA IgG
Architect Positive 14 0 1.00 (1.00–1.00) 100.0 (78.5–100.0) 100.0 (64.6–100.0)
Negative 0 7
Liaison Positive 13 0 0.90 (0.70–1.00) 92.9 (68.5–98.7) 100.0 (64.6–100.0)
Negative 1 7
Platelia Positive 13 0 0.90 (0.70–1.00) 92.9 (68.5–98.7) 100.0 (64.6–100.0)
Negative 1 7
Abbreviations: CI, confidence interval; EBNA, Epstein-Barr virus nuclear antigen; VCA, viral capsid antigen.
Table 3. Results of EBV antibody and DNA assays
EBV DNA VCA IgM/VCA IgG/EBNA IgG panel Architect Liaison Platelia
EBV DNA Positive (N=74) -/-/- Seronegative 2 3 8
+/-/- Early phase acute primary infection 3 0 5
+/+/- Acute primary infection 9 9 0
+/+/+ Transient infection/Re-infection 0 1 0
-/+/+ Past infection 53 49 48
-/+/- Isolated VCA IgG 7 12 10
-/-/+ Isolated EBNA IgG 0 0 3
EBV DNA Negative (N=205) -/-/- Seronegative 37 35 40
+/-/- Early phase acute primary infection 1 1 0
+/+/- Acute primary infection 0 0 0
+/+/+ Transient infection/Re-infection 3 3 0
-/+/+ Past infection 159 147 144
-/+/- Isolated VCA IgG 5 12 8
-/-/+ Isolated EBNA IgG 0 7 13
Abbreviations: EBV, Epstein-Barr virus; VCA, viral capsid antigen; EBNA, Epstein-Barr virus nuclear antigen. 
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DNA-positive samples than in EBV DNA-negative samples for all 
three EBV antibody assays (P =0.02). 
Forty of the 279 patients had confirmed cases of other infec-
tious agents/diseases such as Cytomegalovirus, Mycobacterium 
tuberculosis, and malaria. Six of the 40 patients were positive 
for the EBV DNA test and all were VCA IgM negative according 
to the Architect, Liaison, and Platelia assays. One of the 34 EBV 
DNA-negative patients with another infectious disease was VCA 
IgM positive according to the Architect assay. The positive and 
negative test likelihood ratio and Youden’s index according to 
EBV DNA test, VCA IgM test, and assay combination results were 
evaluated based on the clinical diagnosis of the 279 patients 
(Table 4). For the Architect and Liaison assays, a combination 
of VCA IgM and EBV DNA results was better than the EBV DNA 
test alone. 
3.  Comparisons between the Architect, Liaison, and Platelia 
EBV antibody assays
The Architect and Liaison assays exhibited kappa coefficients of 
0.79 for VCA IgM, 0.80 for VCA IgG, and 0.92 for EBNA IgG, in-
dicating excellent agreement between the two assays (Table 5). 
We observed excellent agreement between the Architect and 
Platelia assays and between the Liaison and Platelia assays for 
EBNA IgG (kappa coefficients, 0.89 and 0.88, respectively). The 
kappa coefficients showed fair and good agreement between 
the Architect and Platelia assays and between the Liaison and 
Table 4. Diagnostic performance of single and combination assays 
Assays Youden’s index
Likelihood ratio
Positive test (95% CI) Negative test (95% CI)
EBV DNA 0.73 4.40 (3.17–5.68) 0.08 (0.01–0.36)
Architect VCA IgM 0.60 27.40 (11.39–63.64) 0.38 (0.19–0.63)
VCA IgM and EBV DNA 0.78 4.53 (3.52–5.73) 0.00 (0.00–0.25)
EBV Antibody and EBV DNA 0.15 1.17 (0.95–1.24) 0.00 (0.00–1.33)
Liaison VCA IgM 0.54 29.59 (11.31–74.70) 0.45 (0.24–0.68)
VCA IgM and EBV DNA 0.78 4.53 (3.52–5.73) 0.00 (0.00–0.25)
EBV Antibody and EBV DNA 0.13 1.15 (0.93–1.22) 0.00 (0.00–1.48)
Platelia VCA IgM 0.25 66.75 (10.15–418.62) 0.75 (0.51–0.90)
VCA IgM and EBV DNA 0.73 4.40 (3.17–5.68) 0.08 (0.01–0.36)
EBV Antibody and EBV DNA 0.15 1.18 (0.95–1.25) 0.00 (0.00–1.29)
Abbreviations: CI, confidence interval; VCA, viral capsid antigen.
Table 5. Agreement between the Architect, Liaison, and Platelia assays
Agreement (95% CI) Architect vs Liaison Architect vs Platelia Liaison vs Platelia
VCA IgM Kappa 0.79 (0.62–0.95) 0.46 (0.20–0.72) 0.51 (0.24–0.79)
Total, % 97.8 (95.4–99.0) 96.1 (93.1–97.8) 96.8 (94.0–98.3)
Negative, % 98.5 (96.2–99.4) 100.0 (98.6–100) 100.0 (98.6–100)
Positive, % 85.7 (60.1–96.0) 31.3 (14.2–55.6) 35.7 (16.3–61.2)
VCA IgG Kappa 0.80 (0.70–0.90) 0.69 (0.59–0.79) 0.64 (0.53–0.75)
Total, % 94.6 (91.3–96.7) 90.0 (85.9–93.0) 88.2 (83.9–91.5)
Negative, % 80.4 (66.8–89.3) 97.7 (87.9–99.6) 89.1 (77.0–95.3)
Positive, % 97.4 (94.5–98.8) 88.6 (83.9–92.0) 88.0 (83.2–91.6)
EBNA IgG Kappa 0.92 (0.87–0.98) 0.89 (0.83–0.95) 0.88 (0.81–0.94)
Total, % 97.1 (94.4–98.5) 96.1 (93.1–97.8) 95.3 (92.2–97.3)
Negative, % 88.9 (79.6–94.3) 96.9 (89.3–99.1) 90.3 (81.3–95.2)
Positive, % 100.0 (98.2–100.0) 95.8 (92.2–97.8) 97.1 (93.8–98.7)
Abbreviations: CI, confidence interval; VCA, viral capsid antigen; EBNA, Epstein-Barr virus nuclear antigen.
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Platelia assays for VCA IgM and VCA IgG. The percentage of posi-
tive agreement for VCA IgM was relatively low when comparing 
the Liaison and Platelia assays and the Architect and Platelia 
assays, because the Platelia assay had a lower VCA IgM positiv-
ity rate than the other assays as well as because of the overall 
low prevalence of VCA IgM-positive samples.
DISCUSSION
We evaluated the diagnostic performance of the Architect CMIA, 
Liaison CLIA, and Platelia ELISA EBV assays (VCA IgM, VCA IgG, 
and EBNA IgG antibodies) using an EBV performance panel as 
a reference. The EBV performance panel results indicated that 
the three EBV antibody assays showed excellent agreement for 
VCA IgM and EBNA IgG; however, the assays exhibited poorer 
VCA IgG detection than the performance panel. Although only a 
few VCA IgM-positive panel samples tested negative using the 
three antibody assays, false negative results could affect correct 
EBV infection diagnosis in patients with suspected EBV infec-
tion. Kappa agreement and sensitivity were significantly affected 
because of the limited number of VCA IgM-positive samples in 
the EBV performance panel. The bias of the performance panel 
towards more VCA IgM-negative and VCA IgG-positive and EBNA 
IgG-positive panel members could have caused different agree-
ment results. One EBNA IgG-positive panel sample tested nega-
tive using the Liaison and Platelia assays. 
This panel sample had a past infection status, and the test re-
sult was close to the cut-off value based on the EBV performance 
panel data sheet (Liaison, 33.15 U/mL; Platelia, 1.4 ISR). For 
VCA IgG, the Architect and Liaison assays showed positive re-
sults for two and three VCA IgG-negative panel members, re-
spectively. In contrast, the Platelia assay demonstrated negative 
results for three VCA IgG-positive panel samples. This was likely 
due to differences in detection sensitivity between the assay meth-
ods used in the Architect and Liaison assays (CLIA vs ELISA). 
As the Architect and Liaison assays showed more differences 
in their test results than the Platelia assay compared with the 
performance panel, the kappa agreement and specificity of the 
Architect and Liaison assays were affected more than those of 
the Platelia assay. The percentages of total agreement were 90.5%, 
85.7%, and 85.7% between the EBV performance panel and 
the Architect, Liaison, and Platelia assays, respectively. How-
ever, false-positive and false-negative results have different im-
portance in the field of infection diagnosis; Platelia assay false-
negative cases represented the possibility of missed EBV infec-
tion diagnosis. We hypothesize that the performance panel had 
included more VCA IgM-positive and VCA IgG-negative samples, 
we would have seen excellent agreement and comparable sen-
sitivity and specificity for the three EBV antibody assays. 
When we compared the EBV DNA and VCA IgM antibody re-
sults, we detected significantly higher positivity rates for the EBV 
DNA test. The EBV DNA detection method has a higher sensi-
tivity than serological antibody detection methods and EBV DNA 
can be detected even without EBV infection, as once infected 
with EBV, the virus might be latently present in B lymphocytes 
[8]. Over 80% of clinical samples that tested negative for EBV 
infection using the antibody assays exhibited EBV DNA positiv-
ity. These samples were possibly collected during early infection 
stages (prior to VCA IgM formation); DNA positivity could also 
be due to EBV latency in B lymphocytes. In addition, EBV DNA 
detection can fail at times, despite current EBV infection, be-
cause of Herpesviridae latency in molecular testing [8]. This 
could explain the VCA IgM positivity and EBV DNA negativity in 
a number of samples in our study. An evaluation of the diagnos-
tic performance of the EBV DNA test and EBV antibody assays 
alone or in combination based on the clinical diagnosis of 279 
patients indicated that the performance of the VCA IgM and 
EBV DNA combination was superior to that of the Architect or 
Liaison assay alone. Although most EBV DNA-negative samples 
were also VCA IgM negative and EBV DNA was detected in VCA 
IgM positive samples, the EBV DNA and antibody tests did not 
always show the same results. Therefore, EBV DNA and anti-
body assays should be used complementarily to diagnose the 
EBV infection status of patients. 
The Architect and Liaison assays showed excellent agreement 
for VCA IgM, VCA IgG, and EBNA IgG. The Platelia assay showed 
more negative test results for VCA IgM- and VCA IgG-positive 
panel samples than the Architect and Liaison assays. This dif-
ference in sensitivity between the Platelia and the Architect and 
Liaison assays is most likely due to the fact that the Platelia as-
say uses ELISA, while the Architect and Liaison assays use CMIA 
and CLIA (with fully-automated analyzers), respectively. How-
ever, all kappa coefficients were >0.40; thus, the three EBV as-
says were considered to have fair and excellent agreement. The 
agreements between the different EBV antibody assays were 
comparable with the results of other studies [9-15, 17].
Our study has several limitations. First, the EBV performance 
panel and clinical samples were not tested with the IFA method, 
which is considered the gold standard for VCA IgG and EBNA 
IgG detection. However, excellent sensitivity and specificity have 
been reported for chemiluminescent EBV antibody detection 
assays [12]. In addition, we used a commercial mixed perfor-
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mance panel consisting of various samples of EBV infection sta-
tus to evaluate the diagnostic performance of the EBV antibody 
assays. The standard performance panel, which has been vali-
dated with several widely used EBV antibody assays and known 
EBV infection status, is a valuable evaluation tool for EBV anti-
body detection assays. Second, the study included only a few 
VCA IgM positive clinical and performance panel samples. There-
fore, evaluating the accuracy of positive results for the VCA IgM 
assays was difficult and the agreement values between the dif-
ferent assays were likely affected. As EBV infection mostly oc-
curs during childhood and adolescence and young patients typ-
ically do not show severe symptoms, the number of samples 
with new infection status was limited. Finally, we did not com-
pare the EBV DNA test with the performance panel because of 
insufficient material. This may help explain the discrepancies in 
test results between the EBV DNA and antibody tests. Future 
studies including a sufficient number of samples with validated 
EBV infection status should be conducted to address this dis-
crepancy and to accurately evaluate the diagnostic performance 
of the EBV assays.
Despite these limitations, to the best of our knowledge, this is 
the first study to evaluate the diagnostic performance of the Ar-
chitect, Liaison, and Platelia EBV antibody assays using a stan-
dard performance panel. The diagnostic performances of the 
three EBV antibody assays using a combination of VCA IgM, VCA 
IgG, and EBNA IgG antibodies were acceptable. In addition, the 
three EBV antibody assays showed good agreement for the clini-
cal samples. A combination of the EBV DNA and VCA IgM anti-
body tests would provide better diagnostic performance for pa-
tients with suspected EBV infection. 
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